Clinical Trial: A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma

U.S., Nov. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07250594) titled 'A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma' on Sept. 04.

Brief Summary: 1. Eosinophilic asthma, a type 2 immune disorder, often involves the excessive production of type 2 cytokines.

2. Excessive Type 2 cytokines lead to chronic inflammation, airway hyperresponsiveness, and airflow obstruction.

3. AD17002 is an intranasal self-applicable immunomodulator.

4. AD17002 is safe and tolerable in all studied clinical trials.

5. AD17002 elevates local type-1 interferon levels and promotes epithelial healing.

6. Type-1 interferons have been demonstrated to rest...